263.
Salih BA, Abasiyanik MF, Saribasak H, et al. A follow-up study on the effect of
Helicobacter pylori eradication on the severity of gastric histology. Dig Dis Sci
2005;50:1517e22.
264.
Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body
gastritis patients: atrophy and intestinal metaplasia are persistent lesions
irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther
2005;22:471e81.
265.
Arkkila PE, Seppala K, Farkkila MA, et al. Helicobacter pylori eradication in the
healing of atrophic gastritis: a one-year prospective study. Scand J Gastroenterol
2006;41:782e90.
266.
Toyokawa T, Suwaki K, Miyake Y, et al. Eradication of Helicobacter pylori infection
improved gastric mucosal atrophy and prevented progression of intestinal
metaplasia, especially in the elderly population: a long-term prospective cohort
study. J Gastroenterol Hepatol 2010;25:544e7.
267.
Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on
incidence of metachronous gastric carcinoma after endoscopic resection of early
gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392e7.
268.
Kosunen TU, Pukkala E, Sarna S, et al. Gastric cancers in Finnish patients after
cure of Helicobacter pylori infection: a cohort study. Int J Cancer 2011;128:433e9.
269.
Ogura K, Hirata Y, Yanai A, et al. The effect of Helicobacter pylori eradication on
reducing the incidence of gastric cancer. J Clin Gastroenterol 2008;42:279e83.
270.
Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the
incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther
2007;25:805e12.
271.
Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on
subsequent development of cancer after endoscopic resection of early gastric
cancer. Cancer Epidemiol Biomark Prev 1997;6:639e42.
272.
Wu CY, Kuo KN, Wu MS, et al. Early Helicobacter pylori eradication decreases risk
of gastric cancer in patients with peptic ulcer disease. Gastroenterology
2009;137:1641e8.
273.
Ito M, Takata S, Tatsugami M, et al. Clinical prevention of gastric cancer by
Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol
2009;44:365e71.
274.
De Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric
cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104:1342e5.
275.
Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of helicobacter
pylori in the East and West. Expert Rev Anti Infect Ther 2011;9:581e8.
276.
Yeh JM, Kuntz KM, Ezzati M, et al. Exploring the cost-effectiveness of Helicobacter
pylori screening to prevent gastric cancer in China in anticipation of clinical trial
results. Int J Cancer 2009;124:157e66.
277.
Shin DW, Yun YH, Choi IJ, et al. Cost-effectiveness of eradication of Helicobacter
pylori in gastric cancer survivors after endoscopic resection of early gastric cancer.
Helicobacter 2009;14:536e44.
278.
Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and
secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomark Prev
2007;16:875e85.
279.
Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet
2009;374:1449e61.
280.
Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus
document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
use. Am J Gastroenterol 2008;103:2890e907.
281.
Targownik LE, Metge CJ, Leung S. Underutilization of gastroprotective strategies
in aspirin users at increased risk of upper gastrointestinal complications. Aliment
Pharmacol Ther 2008;28:88e96.
282.
Ford AC, Forman D, Bailey AG, et al. A community screening program for
Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial.
Gastroenterology 2005;129:1910e17.
283.
Hansen JM, Wildner-Christensen M, Hallas J, et al. Effect of a community
screening for Helicobacter pylori: a 5-Yr follow-up study. Am J Gastroenterol
2008;103:1106e13.
284.
van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did
anything change? Time trend analysis of incidence and outcome of acute upper GI
bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003;98:1494e9.
285.
Gonzalez CA, Lopez-Carrillo L. Helicobacter pylori, nutrition and smoking
interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol
2010;45:6e14.
286.
Miki K, Morita M, Sasajima M, et al. Usefulness of gastric cancer screening using
the serum pepsinogen test method. Am J Gastroenterol 2003;98:735e9.
287.
Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis
2007;8:8e14.
288.
Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric
Cancer 2006;9:245e53.
289.
De Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications
for the development of screening and surveillance strategies. Helicobacter 2007;12
(Suppl 2):22e31.
290.
Rugge M, Kim JG, Mahachai V, et al. OLGA gastritis staging in young adults and
country-specific gastric cancer risk. Int J Surg Pathol 2008;16:150e4.
291.
Rugge M, de BM, Pennelli G, et al. OLGA can guard the barn. Am J Gastroenterol
2009;104:3099e2.
292.
Rugge M, de BM, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk:
a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther
2010;31:1104e11.
293.
Capelle LG, De Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA
system by using intestinal metaplasia as an accurate alternative for atrophic
gastritis. Gastrointest Endosc 2010;71:1150e8.
294.
Rokkas T, Sechopoulos P, Pistiolas D, et al. Helicobacter pylori infection and gastric
histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J
Gastroenterol Hepatol 2010;22:1128e33.
295.
Chen MJ, Wu DC, Ko YC, et al. Personal history and family history as a predictor of
gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. Am J
Gastroenterol 2004;99:1250e7.
296.
Foschi R, Lucenteforte E, Bosetti C, et al. Family history of cancer and stomach
cancer risk. Int J Cancer 2008;123:1429e32.
297.
Gao Y, Hu N, Han X, et al. Family history of cancer and risk for esophageal and
gastric cancer in Shanxi, China. BMC Cancer 2009;9:269.
298.
Kondo T, Toyoshima H, Tsuzuki Y, et al. Aggregation of stomach cancer history in
parents and offspring in comparison with other sites. Int J Epidemiol 2003;32:579e83.
299.
Munoz N, Plummer M, Vivas J, et al. A case-control study of gastric cancer in
Venezuela. Int J Cancer 2001;93:417e23.
300.
Shin CM, Kim N, Yang HJ, et al. Stomach cancer risk in gastric cancer relatives:
interaction between Helicobacter pylori infection and family history of gastric cancer
for the risk of stomach cancer. J Clin Gastroenterol 2010;44:e34e9.
301.
Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and
management. Clin Gastroenterol Hepatol 2006;4:262e75.
302.
Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is
prophylactic total gastrectomy indicated? Cancer 2001;92:181e7.
303.
Cisco RM, Norton JA. Hereditary diffuse gastric cancer: surgery, surveillance and
unanswered questions. Future Oncol 2008;4:553e9.
304.
Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary
diffuse gastric cancer. Gut 2004;53:775e8.
305.
Lynch HT, Silva E, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: prophylactic
surgical oncology implications. Surg Clin North Am 2008;88:759e78. vievii.
306.
Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for
germline mutations in E-cadherin (CDH1): pathologic findings with clinical
implications. Am J Surg Pathol 2008;32:799e809.
307.
Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line
mutation of the E-cadherin gene: implications for genetic testing and clinical
management. Clin Cancer Res 2005;11:5401e9.
308.
Sinning C, Schaefer N, Standop J, et al. Gastric stump carcinoma - epidemiology and
current concepts in pathogenesis and treatment. Eur J Surg Oncol 2007;33:133e9.
309.
Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for
benign disorders. Arch Intern Med 1990;150:2022e6.
310.
Tersmette AC, Offerhaus GJ, Tersmette KW, et al. Meta-analysis of the risk of
gastric stump cancer: detection of high risk patient subsets for stomach cancer after
remote partial gastrectomy for benign conditions. Cancer Res 1990;50:6486e9.
311.
Tersmette AC, Giardiello FM, Tytgat GN, et al. Carcinogenesis after remote peptic
ulcer surgery: the long-term prognosis of partial gastrectomy. Scand J Gastroenterol
Suppl 1995;212:96e9.
312.
Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk
of gastric cancer: a population-based cohort study. Br J Cancer 2009;100:1503e7.
313.
Chung HW, Noh SH, Lim JB. Analysis of demographic characteristics in 3242 young
age gastric cancer patients in Korea. World J Gastroenterol 2010;16:256e63.
314.
Sjodahl K, Lu Y, Nilsen TI, et al. Smoking and alcohol drinking in relation to risk of
gastric cancer: a population-based, prospective cohort study. Int J Cancer
2007;120:128e32.
315.
Azevedo NF, Huntington J, Goodman KJ. The epidemiology of Helicobacter pylori
and public health implications. Helicobacter 2009;14(Suppl 1):1e7.
316.
Miendje Deyi VY, Vanderpas J, Bontems P, et al. Marching cohort of Helicobacter
pylori infection over two decades (1988-2007): combined effects of secular trend
and population migration. Epidemiol Infect 2011;139:572e80.
317.
Kato M, Asaka M. Recent knowledge of the relationship between Helicobacter
pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and
treatment for gastric cancer. Jpn J Clin Oncol 2010;40:828e37.
318.
Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing
countries: meta-analysis of 13C-urea breath test follow-up after eradication.
Helicobacter 2008;13:56e61.
319.
De Francesco V, Margiotta M, Zullo A, et al. Claritromycin resistance and
Helicobacter pylori genotypes in Italy. J Microbiol 2006;44:660e4.
320.
Agudo S, Perez-Perez G, Alarcon T, et al. High prevalence of clarithromycin-
resistant Helicobacter pylori strains and risk factors associated with resistance in
Madrid, Spain. J Clin Microbiol 2010;48:3703e7.
321.
Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health
implications. Helicobacter 2010;15(Suppl 1):1e6.
322.
Rupnow MF, Chang AH, Shachter RD, et al. Cost-effectiveness of a potential
prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis
2009;200:1311e17.
323.
Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against
Helicobacter pylori. Expert Rev Vaccines 2009;8:1037e49.
324.
Aebischer T, Bumann D, Epple HJ, et al. Correlation of T cell response and
bacterial clearance in human volunteers challenged with Helicobacter pylori
revealed by randomised controlled vaccination with Ty21a-based Salmonella
vaccines. Gut 2008;57:1065e72.
325.
McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med
2010;362:1597e604.
664
Gut 2012;61:646e664. doi:10.1136/gutjnl-2012-302084
Guidelines